Log in with your email address username.


[Correspondence] Safety and efficacy of statins – Authors’ reply

The comments by Simon Dimmitt and colleagues have already been addressed in a response to a previous letter from them.1 In particular, lowering LDL cholesterol more intensively with higher-dose statin therapy has been shown to produce larger reductions in vascular events than with smaller LDL reductions. With respect to the suggestion that adverse effects contribute to more than half of patients discontinuing statin therapy, results from randomised masked trials have shown that patients are no more likely to discontinue statin therapy than placebo; that is, Dimmitt and colleagues confuse attribution with causation (as did John Abramson and colleagues2,3).